What is the recommended management and treatment for human metapneumovirus infection?

Management and Treatment of Human Metapneumovirus Infection

For most patients with human metapneumovirus (hMPV) infection, treatment remains supportive care only, as no specific antivirals or vaccines are currently approved for clinical use. 1, 2, 3

Diagnostic Approach

Testing should be performed in high-risk populations to guide infection control and clinical decisions:

• HSCT candidates, HSCT recipients, and hematological patients with upper or lower respiratory tract disease should be tested for hMPV as part of community-acquired respiratory virus (CARV) panel to guide infection control measures and treatment decisions 4
• Specimens should be collected from the site of clinical involvement: pooled swabs for upper respiratory tract disease, or bronchoalveolar lavage (BAL) for lower respiratory tract disease 4
• Testing for hMPV should be considered based on local epidemiology or when first-line testing for influenza, RSV, and parainfluenza is negative 4

Treatment Strategy by Patient Population

Immunocompetent Patients

Supportive care is the only recommended management:

• No specific antiviral therapy is indicated or available 1, 2, 3
• Treatment focuses on symptom management including hydration, antipyretics, and respiratory support as needed 2
• Hospitalization may be required for infants with significant respiratory distress 2

Immunocompromised and Hematological Patients

The evidence for specific antiviral treatment in immunocompromised patients is limited, but extrapolation from RSV guidelines suggests potential approaches:

• While the 2013 ECIL-4 guidelines do not provide specific recommendations for hMPV treatment, they acknowledge hMPV as a CARV requiring diagnostic testing 4
• The guidelines recommend ribavirin (aerosolized or systemic) for RSV in similar patient populations, but no formal recommendation exists for hMPV 4
• Withholding specific antiviral treatment may be considered for stable patients after careful risk assessment 4

Severe ARDS Cases

For life-threatening respiratory failure:

• Maximal medical support including lung-protective ventilation strategies should be implemented 3
• Veno-venous extracorporeal membrane oxygenation (V-V ECMO) should be considered as rescue therapy for refractory, life-threatening hypoxemia despite maximal conventional support 3
• Early application of V-V ECMO may be lifesaving in severe cases 3

Emerging Therapies (Not Yet Approved)

Several investigational approaches show promise but remain unavailable for clinical use:

• Monoclonal antibodies targeting the hMPV fusion protein (such as mAb364/MPV364) demonstrate potent neutralizing activity in preclinical studies 5, 1
• Intranasal delivery of neutralizing antibodies appears more effective than systemic administration for established infections, reducing viral titers by approximately four logs within 2 days in animal models 5
• Repurposed antivirals including ribavirin and probenecid have been explored but none are approved 1
• Multiple vaccine platforms (subunit, live attenuated, vector-based, and mRNA) are in development but none have reached licensure 1

Key Clinical Pitfalls

Common mistakes to avoid:

• Do not assume hMPV infection is always mild—it can cause severe pneumonia and ARDS requiring intensive care 6, 3
• Do not overlook hMPV in elderly, immunocompromised, or patients with chronic lung disease (COPD, asthma) where exacerbations may occur 2
• Do not delay diagnostic testing in high-risk hematological patients, as early identification guides infection control even without specific therapy 4
• Laboratory findings may include leukocytosis, leukopenia, neutrophilia, lymphopenia, and elevated inflammatory markers 2